NCT07177300 - Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Sickle Cell Anemia (HbSS)Sickle-β0-thalassemia (HbSβ0)

Interventions

DRUG

PK-optimized oral hydroxyurea at MTD until 15 years of age.

Because people are different, we will measure how each participant's body absorbs and eliminates the medicine, hydroxyurea, using blood tests. This information will be used to determine the best dose for each participant (rather than using the same weight-based dose for everyone).

Trial Locations (1)

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors

collaborator

Greater Cincinnati Foundation

UNKNOWN

lead

Children's Hospital Medical Center, Cincinnati

OTHER